• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»aesthetic dermatology

How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem

By Pallavi Madhiraju on April 16, 2026   Pharma & Biotech  

How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem

Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

By Pallavi Madhiraju on February 12, 2026   Pharma & Biotech  

How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine

Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.

Cynosure Lutronic sets stage for global Mosaic 3D rollout with IMCAS 2026 momentum

By Pallavi Madhiraju on February 2, 2026   Medical Devices & Diagnostics  

Cynosure Lutronic sets stage for global Mosaic 3D rollout with IMCAS 2026 momentum

Find out how Cynosure Lutronic’s Mosaic 3D laser device could redefine non-ablative resurfacing after CE mark approval under EU MDR.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes